Liposarcoma Pipeline Insight 2025: 15+ Pipeline Drugs, Targeted Therapies, and Immuno-Oncology Strategies Shape Future Care | DelveInsight

DelveInsight's "Liposarcoma - Pipeline Insight, 2025" explores over 15+ therapies in development for liposarcoma, a rare and heterogeneous soft tissue sarcoma subtype. Despite surgery and radiotherapy being standard in localized disease, patients with advanced or recurrent tumors face limited systemic options, leaving significant unmet needs in the liposarcoma treatment market.

The liposarcoma pipeline is diversifying with next-generation targeted therapies, including CDK4 and MDM2 inhibitors, angiogenesis blockers, and drugs directed at fusion oncoproteins like FUS-DDIT3. Immuno-oncology is also advancing, with checkpoint inhibitors and cancer vaccines being tested across liposarcoma subtypes. In addition, novel antibody-drug conjugates and cell-based therapies are under evaluation, aiming to expand beyond the modest outcomes of current chemotherapies in the liposarcoma treatment landscape.

With liposarcoma clinical trials spanning small molecules, biologics, and immunotherapies, the therapeutic focus is shifting toward subtype-specific precision strategies. As these candidates progress through late-stage development, the liposarcoma market is expected to evolve, moving from a chemotherapy-dominated space to one defined by targeted and immune-driven treatments that can extend survival and improve quality of life for patients with this rare cancer.

Interested in learning more about the current treatment landscape and the key drivers shaping the Liposarcoma pipeline? Click here: https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Liposarcoma Pipeline Report
• DelveInsight's Liposarcoma pipeline analysis depicts a strong space with 15+ active players working to develop 20+ pipeline drugs for Liposarcoma treatment.
• The leading Liposarcoma companies include Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc, Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc., and others are evaluating their lead assets to improve the Liposarcoma treatment landscape.
• Key Liposarcoma pipeline therapies in various stages of development include Brigimadlin, APG-115, BTX-A51, SPH4336, Seclidemstat, SA53-OS, PF-07220060, PeptiCRAd-1, OR2805, Letetresgene autoleucel, INCMGA00012, DS-2243a, NM32-2668, MASCT-I, CAR-GPC3 T Cells, and others.
• In January 2025, the FDA granted Breakthrough Therapy Designation to lete-cel (letetresgene autoleucel) for patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have previously undergone anthracycline-based chemotherapy. This designation was based on Phase II data showing a 42% overall response rate and a median response duration of 12.2 months in the IGNYTE-ESO trial.

Request a sample and discover the recent breakthroughs happening in the Liposarcoma pipeline landscape at https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Liposarcoma Overview
Liposarcoma is a rare type of cancer that originates in fat cells within deep soft tissue, such as that in the thigh, retroperitoneum (the back of the abdominal cavity), or other areas of the body. It is one of the most common types of soft tissue sarcoma in adults. Liposarcomas can vary significantly in their behavior, ranging from slow-growing tumors with low potential for metastasis to aggressive forms that spread rapidly to other organs. There are several subtypes, including well-differentiated, myxoid, round cell, pleomorphic, and dedifferentiated, each with distinct characteristics and prognosis.

Treatment typically involves surgical removal of the tumor, which may be combined with radiation therapy and/or chemotherapy depending on the tumor's size, location, and grade. In cases where complete surgical resection is not possible or in advanced/metastatic disease, systemic therapies including targeted agents or clinical trial options may be considered. Long-term follow-up is essential, as liposarcomas have a risk of recurrence or metastasis, especially in high-grade forms.

Find out more about Liposarcoma medication at https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Liposarcoma Treatment Analysis: Drug Profile
Brigimadlin: Boehringer Ingelheim
Brigimadlin is a potent, orally administered MDM2-p53 antagonist. It works by binding to MDM2 and blocking its interaction with the tumor suppressor protein p53. By preventing MDM2 from inactivating p53, Brigimadlin helps restore p53's tumor-suppressing function. MDM2 is often overexpressed in certain cancers, leading to degradation of p53 and uncontrolled tumor growth. In preclinical studies, Brigimadlin demonstrated single-agent activity in MDM2-amplified dedifferentiated liposarcoma (DDLPS) patient-derived xenograft models and showed enhanced disease control in both xenograft and syngeneic mouse tumor models. The drug is currently in Phase III clinical development for the treatment of liposarcoma.

APG-115: Ascentage Pharma Group Inc.
APG-115 is an oral, selective small-molecule inhibitor designed to block the MDM2-p53 protein-protein interaction. By targeting MDM2, APG-115 reactivates p53, enhancing its tumor-suppressing capabilities. Preclinical data show that APG-115 not only restores p53 function but also stimulates immune activity-promoting proinflammatory cytokine production in T cells, increasing CD4+ T cell activation, and upregulating PD-L1 expression on tumor cells. APG-115 is currently undergoing Phase I/II clinical trials for the treatment of liposarcoma.

CAR-GPC3 T Cells: Sotio Biotech Inc.
CAR-GPC3 T Cells represent an advanced form of CAR T cell therapy, incorporating the GOT2 transgene from Sotio's proprietary BOXR platform. GOT2 plays a key role in cellular metabolism, and its integration enhances T cell function within the challenging environment of solid tumors. These engineered CAR T cells specifically target tumors expressing glypican-3 (GPC3) and have demonstrated promising preclinical efficacy in models that closely mimic the solid tumor microenvironment. CAR-GPC3 T Cells are currently in Phase I/II clinical development for the treatment of liposarcoma.

Learn more about the novel and emerging Liposarcoma pipeline therapies at https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Liposarcoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Liposarcoma Pipeline Report
• Coverage: Global
• Key Liposarcoma Companies: Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc, Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc., and others.
• Key Liposarcoma Pipeline Therapies: Brigimadlin, APG-115, BTX-A51, SPH4336, Seclidemstat, SA53-OS, PF-07220060, PeptiCRAd-1, OR2805, Letetresgene autoleucel, INCMGA00012, DS-2243a, NM32-2668, MASCT-I, CAR-GPC3 T Cells, and others.

To dive deep into rich insights for drugs used for Liposarcoma treatment, visit: https://www.delveinsight.com/report-store/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Liposarcoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Liposarcoma Pipeline Therapeutics
6. Liposarcoma Pipeline: Late-Stage Products (Phase III)
7. Liposarcoma Pipeline: Mid-Stage Products (Phase II)
8. Liposarcoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.